Alp AI

Startup

ALP AI – Immunogenicity Intelligence for Biologics

ALP AI is building the first integrated platform to detect and prevent Anti-Drug Antibody (ADA) responses early in biologics development. We combine human tonsil-derived immune organoids with generative AI to predict real human immunogenicity and re-engineer antibody sequences before they enter costly clinical stages.

While AI enables rapid generation of novel antibodies, immunogenicity remains a major hidden failure risk. Our platform closes this gap by providing human-relevant immune feedback and AI-guided sequence optimization in a continuous learning loop.

We work with biotech and pharma partners on ADA risk assessment, asset de-immunization, and co-development of low-immunogenicity biobetters.

Our goal: ensure promising biologics survive the immune system and reach patients safely and efficiently.

website